Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparative Trial of the Efficacy of Two Different Nolvadex (NDX) Dosing and Scheduling Regimens in Preventing Gynecomastia Induced by Casodex (CDX) 150 Monotherapy in Prostate Cancer Patients. An Open, Multicenter, Phase III Trial.

NCT00233610 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00233610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00233610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparative Trial of the Efficacy of Two Different Nolvadex (NDX) Dosing and Scheduling Regimens in Preventing Gynecomastia Induced by Casodex (CDX) 150 Monotherapy in Prostate Cancer Patients. An Open, Multicenter, Phase III Trial.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2003
Completion date
October 31, 2007
Enrollment
180
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer